CJC-1295 No DAC (10mg) / Ipamorelin (10mg)
Combined formulation of two synthetic peptides extensively paired in growth hormone secretagogue research: CJC-1295 No DAC (a GHRH analog) and Ipamorelin (a selective ghrelin receptor agonist).
About this formulation
This product combines two synthetic peptides that appear together throughout growth hormone secretagogue research:
- CJC-1295 No DAC (10mg) — a 29-amino-acid GHRH analog acting at GHRH receptors in the pituitary
- Ipamorelin (10mg) — a selective ghrelin/GHSR-1a receptor agonist with high specificity (minimal observed effects on cortisol, prolactin, or aldosterone in research)
Mechanism in Research Literature
The two peptides act on parallel GH-release pathways:
- CJC No DAC: GHRH receptor activation — "permissive" signaling
- Ipamorelin: ghrelin receptor activation — "stimulatory" signaling
- Combined effect: synergistic GH release greater than either compound alone in research models
- Selectivity profile of Ipamorelin reduces off-target signaling observed with earlier GHRPs
- Short half-lives preserve pulsatile GH release pattern
Research Context
This combination has been investigated in studies exploring:
- Synergistic activation of dual GH-release pathways
- Pulsatile vs. continuous GH elevation pharmacology
- Selectivity of Ipamorelin relative to GHRP-2, GHRP-6, and hexarelin
- Downstream IGF-1 response and tissue effects
Related Research Peptides
This combination appears in literature alongside other GH-pathway compounds including Sermorelin, Tesamorelin, IGF-1 LR3, and the standalone CJC No DAC product.
For research and educational use only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.
